Axovant Gene Therapies (NASDAQ:AXGT) Upgraded to Buy by ValuEngine – Slater Sentinel

Posted: January 19, 2020 at 7:42 pm

Axovant Gene Therapies (NASDAQ:AXGT) was upgraded by stock analysts at ValuEngine from a hold rating to a buy rating in a report released on Friday, January 3rd, ValuEngine reports.

A number of other equities research analysts have also commented on the company. Chardan Capital increased their price target on Axovant Gene Therapies from $10.00 to $15.00 and gave the company a buy rating in a research report on Monday, October 28th. Zacks Investment Research raised Axovant Gene Therapies from a hold rating to a strong-buy rating and set a $6.00 price target for the company in a research report on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have assigned a buy rating to the companys stock. The company currently has a consensus rating of Buy and a consensus target price of $24.66.

Shares of NASDAQ:AXGT opened at $4.43 on Friday. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.69. Axovant Gene Therapies has a twelve month low of $3.81 and a twelve month high of $19.60. The stocks 50 day moving average is $5.14 and its 200-day moving average is $6.11. The firm has a market capitalization of $105.98 million, a price-to-earnings ratio of -1.00 and a beta of 1.18.

Large investors have recently made changes to their positions in the business. Tower Research Capital LLC TRC grew its stake in shares of Axovant Gene Therapies by 955.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,221 shares of the companys stock worth $27,000 after acquiring an additional 3,821 shares during the period. Barclays PLC bought a new position in shares of Axovant Gene Therapies during the 3rd quarter worth $65,000. Jane Street Group LLC grew its stake in shares of Axovant Gene Therapies by 28.8% during the 2nd quarter. Jane Street Group LLC now owns 46,455 shares of the companys stock worth $289,000 after acquiring an additional 10,375 shares during the period. Woodstock Corp bought a new position in shares of Axovant Gene Therapies during the 4th quarter worth $83,000. Finally, BlackRock Inc. bought a new position in shares of Axovant Gene Therapies during the 2nd quarter worth $1,482,000. Hedge funds and other institutional investors own 14.80% of the companys stock.

Axovant Gene Therapies Company Profile

Axovant Gene Therapies Ltd., a clinical-stage gene therapy company, focuses on developing a pipeline of product candidates for debilitating neurological and neuromuscular diseases. The company's current pipeline of gene therapy candidates targets GM1 gangliosidosis, GM2 gangliosidosis, Parkinson's disease, oculopharyngeal muscular dystrophy, amyotrophic lateral sclerosis, and frontotemporal dementia.

Featured Story: What is the price-sales ratio?

To view ValuEngines full report, visit ValuEngines official website.

Receive News & Ratings for Axovant Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.

More here:
Axovant Gene Therapies (NASDAQ:AXGT) Upgraded to Buy by ValuEngine - Slater Sentinel

Related Post

Comments are closed.

Archives